MACSF

COMMUNIQUÉS West-GlobeNewswire

BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights
08/05/2024
Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Third Consecutive [...]
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
08/05/2024
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
08/05/2024
SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM ( C linical E valuation of D osing with A ficamten to R educe Obstruction in a [...]
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
08/05/2024
WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical [...]
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
08/05/2024
— New therapeutic candidate developed using Company’s patented ThermoStem ® platform — — Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and marketed towards weight loss [...]
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
08/05/2024
Data Support Advancement to Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 Full Data from the Phase 1 Study to be Presented at a Medical Congress in [...]
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
08/05/2024
Virtual R&D event to be held on June 5, 2024 from 12:00 to 2:00 PM EDT – highlighting company plans for INF904 and the opportunity, the role of C5aR in ch ronic spontaneous urticaria (CSU) and hidradenitis [...]
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
08/05/2024
- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: [...]
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
08/05/2024
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its [...]
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
08/05/2024
Olema will host an investor conference call at 8:00 a.m. ET on May 15, 2024 SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage [...]
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
08/05/2024
STAMFORD, Conn., May 08, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management [...]
Immunocore reports first quarter financial results and provides a business update
08/05/2024
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches [...]
Body & Brain Yoga Tai Chi to Provide Online Wellness Sessions for AARP Audience
08/05/2024
Body & Brain Yoga Tai Chi is excited to announce a new collaboration with AARP, where they will provide online wellness sessions for AARP’s audience MESA, Ariz., May 08, 2024 (GLOBE NEWSWIRE) -- Body & Brain [...]
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
08/05/2024
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that Dr Renu Bhatia is appointed [...]
ENA Respiratory Receives USPTO Notice of Allowance for Key Patent Covering INNA-051, a First-in-Class Antiviral Innate Immunomodulator
08/05/2024
MELBOURNE, Australia, May 08, 2024 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral [...]
First Quarter 2024: Strong growth in US sales of The NGAL Test
08/05/2024
May 8, 2024 Announcement no. 11 First Quarter 2024: Strong growth in US sales of The NGAL Test COPENHAGEN, Denmark and BOSTON, MA, USA, May 8, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S CVR-no. 17500317 (BioPorto or Company [...]
Finnish Hospital Orders Nexstim NBS System 5
08/05/2024
Press release, Helsinki, 8 May 2024 at 9 AM (EEST) Finnish Hospital Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a hospital in Finland. This [...]
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
08/05/2024
COPENHAGEN, Denmark, May 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 162,288 of its own shares. The purpose [...]
Bavarian Nordic Announces Interim Results for the First Three Months of 2024
08/05/2024
COPENHAGEN, Denmark , May 8, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2024. Revenue for the first three months was DKK 831 [...]

Pages